The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Design of a phase II randomized, open-label trial of DN24-02, an autologous cellular immunotherapy targeting HER2/neu, in patients with surgically resected urothelial cancer at high risk of recurrence.
D. F. Bajorin
Consultant or Advisory Role - Bristol-Myers Squibb; Dendreon; GlaxoSmithKline
Honoraria - Lilly
Research Funding - Amgen; Genentech; Genta
P. Sharma
Consultant or Advisory Role - Dendreon
Honoraria - Dendreon
R. B. Sims
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
A. Sandler
Employment or Leadership Position - Dendreon
Stock Ownership - Dendreon
S. P. Lerner
Consultant or Advisory Role - Dendreon